Table 4 The cumulative calculation for patients with treatment-emergent oncogenic alterations

TP53

30 (42.3%)

8 (28.6%)

0.207

T790M

29 (40.8%)

18 (64.3%)

0.035

Unknown

17 (23.9%)

6 (21.4%)

0.790

PIK3CA

7 (9.9%)

1 (3.6%)

0.435

EGFR amp

7 (9.9%)

0 (0.0%)

0.186

PTEN

4 (5.6%)

1 (3.6%)

1

APC

4 (5.6%)

0 (0.0%)

0.575

Met amp

2 (2.8%)

1 (3.6%)

1

KRAS

2 (2.8%)

1 (3.6%)

1

GRM3

2 (2.8%)

0 (0.0%)

1

RET

2 (2.8%)

0 (0.0%)

1

BRAF

1 (1.4%)

1 (3.6%)

0.488

ATM

1 (1.4%)

1 (3.6%)

0.492

mTOR

1 (1.4%)

1 (3.6%)

0.488

FGFR3-TACC3[F17,T10]

1 (1.4%)

0 (0.0%)

1

EGFR18 pE709A

1 (1.4%)

0 (0.0%)

1

SMAD4

1 (1.4%)

0 (0.0%)

1

ERBB2 amp

1 (1.4%)

0 (0.0%)

1

FGFR1 amp

1 (1.4%)

0 (0.0%)

1

EGFR 21 p.L844V

1 (1.4%)

0 (0.0%)

1

EGFR 20 ins

1 (1.4%)

0 (0.0%)

1

EGFR 19(L747_P752>S)

1 (1.4%)

0 (0.0%)

1

EGFR 27 p.Y1069C

1 (1.4%)

0 (0.0%)

1

EGFR 18 p.G724S

1 (1.4%)

0 (0.0%)

1

TGF β1

1 (1.4%)

0 (0.0%)

1

VOPP1-EGFR [V2,E27]

1 (1.4%)

0 (0.0%)

1

STK11

1 (1.4%)

0 (0.0%)

1

EGFR 19 p.A755D

0 (0.0%)

1 (3.6%)

0.283

RB1

0 (0.0%)

1 (3.6%)

0.283